Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma
Journal of Visualized Experiments · 2026
DOI: 10.3791/69890 ↗At a glance
Video/Audio in Journal of Visualized Experiments, 2026. Written by Shuiling Xie and 3 co-authors. Institution: The First Affiliated Hospital of Gannan Medical University. Major MEDLINE topics: Multiple Myeloma, High-Throughput Nucleotide Sequencing.
Abstract (original language)
Minimal residual disease (MRD) detection is crucial for managing lymphoid malignancies. This study introduces OriMIRACLE LTM, a novel next-generation sequencing (NGS)-based B-cell receptor (BCR) and T-cell receptor (TCR) clonality assay for MRD detection. We validated the assay using cell lines and clinical samples, including residual smears, from patients with Multiple Myeloma (MM). The BCR/TCR clonality assay demonstrated an over 90% positive detection rate in lymphoid malignancies. Validation studies in MM patients demonstrated an 81.36% (48/59) concordance rate between multicolor flow cytometry (MFC) and clinical response assessment in tumor cell detection. Notably, 61.11% (11/18) of MM patients positive for MRD by both NGS and MFC experienced disease progression or relapse. Patients with MRD detected solely by NGS exhibited lower clinical complete response rates, and some initially responsive MM patients relapsed after treatment cessation. These findings indicate that this NGS-based assay offers highly sensitive and specific MRD detection in lymphoid malignancies, even in MM patient-derived residual smear samples. It demonstrates advantages over MFC and proves valuable for MRD tracking. In conclusion, current evidence supports NGS as a complementary tool to MFC, particularly in MFC⁻/NGS⁺ patients, as NGS offers deeper risk stratification. However, the optimal intervention threshold remains to be determined by prospective studies.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- The First Affiliated Hospital of Gannan Medical University.
- The First Affiliated Hospital of Gannan Medical University; lcm1430@163.com.
Cite
APA
Xie, S., Liao, C., Xin, L., & Lin, C. (2026). Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma. Journal of Visualized Experiments. https://doi.org/10.3791/69890
Vancouver
Xie S, Liao C, Xin L, Lin C. Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma. Journal of Visualized Experiments. 2026. doi:10.3791/69890
BibTeX
@article{Xie2026,
author = {Xie, Shuiling and Liao, Changfeng and Xin, Liuyan and Lin, Chuanming},
title = {Next-Generation Sequencing Clonality Assays: Clinical Validation for Minimal Residual Disease Monitoring in Multiple Myeloma},
journal = {Journal of Visualized Experiments},
year = {2026},
doi = {10.3791/69890}
}
EUVIMED